Patents by Inventor William M. Siders
William M. Siders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945874Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: GrantFiled: March 3, 2021Date of Patent: April 2, 2024Assignee: Genzyme CorporationInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20220010024Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: March 3, 2021Publication date: January 13, 2022Applicant: Genzyme CorporationInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20210228564Abstract: The disclosure relates to a method of treating cancer by administering to the subject a therapeutically effective amount of a composition comprising pyrvinium pamoate, optionally in combination with at least one additional therapeutic agent or modality.Type: ApplicationFiled: January 13, 2021Publication date: July 29, 2021Inventors: Katherine ARLINE, Jamie Dempsey BARBER, William M. SIDERS, Johanne KAPLAN
-
Publication number: 20210171948Abstract: The disclosure relates to dsRNAs and siRNAs targeting glypican-2 (GPC2) and nanoparticles comprising same, for the treatment of cancer.Type: ApplicationFiled: December 9, 2020Publication date: June 10, 2021Inventors: William M. SIDERS, Rajesha RUPAIMOOLE
-
Patent number: 10933061Abstract: The disclosure relates to a method of treating cancer by administering to the subject a therapeutically effective amount of a composition comprising pyrvinium pamoate, optionally in combination with at least one additional therapeutic agent or modality.Type: GrantFiled: December 21, 2018Date of Patent: March 2, 2021Assignee: Shepherd Therapeutics, Inc.Inventors: Katherine Arline, Jamie Dempsey Barber, William M. Siders, Johanne Kaplan
-
Publication number: 20200040091Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: April 10, 2019Publication date: February 6, 2020Applicant: GENZYME CORPORATIONInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20190209549Abstract: The disclosure relates to a method of treating cancer by administering to the subject a therapeutically effective amount of a composition comprising pyrvinium pamoate, optionally in combination with at least one additional therapeutic agent or modality.Type: ApplicationFiled: December 21, 2018Publication date: July 11, 2019Inventors: Katherine ARLINE, Jamie Dempsey BARBER, William M. SIDERS, Johanne KAPLAN
-
Publication number: 20190175560Abstract: The disclosure relates to a method of treating cancer by administering to the subject a therapeutically effective amount of a composition comprising mebendazole.Type: ApplicationFiled: December 3, 2018Publication date: June 13, 2019Inventors: Jamie Dempsey BARBER, Katherine ARLINE, William M. SIDERS, Johanne KAPLAN
-
Publication number: 20170369583Abstract: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.Type: ApplicationFiled: March 1, 2017Publication date: December 28, 2017Applicant: GENZYME CORPORATIONInventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
-
Patent number: 9617343Abstract: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.Type: GrantFiled: May 13, 2010Date of Patent: April 11, 2017Assignee: GENZYME CORPORATIONInventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
-
Publication number: 20160208010Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: September 24, 2015Publication date: July 21, 2016Inventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20140341910Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: November 26, 2013Publication date: November 20, 2014Applicant: GENZYME CORPORATIONInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Patent number: 8617554Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: GrantFiled: May 13, 2010Date of Patent: December 31, 2013Assignee: Genzyme CorporationInventors: Bruce L Roberts, Srinivas Shankara, William Harold Brondyk, William M Siders
-
Publication number: 20120100152Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: May 13, 2010Publication date: April 26, 2012Applicant: GENZYME CORPORATIONInventors: Bruce L Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20120070408Abstract: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.Type: ApplicationFiled: May 13, 2010Publication date: March 22, 2012Applicant: GENZYME CORPORATIONInventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
-
Publication number: 20120058082Abstract: The invention provides methods for improving the efficacy and reducing side effects of anti-CD52 antibody treatment. The methods can be used to treat patients who are in need of immunoregulation such as lymphocyte depletion and patients who have cancer. Also included are compositions useful for these methods.Type: ApplicationFiled: May 13, 2010Publication date: March 8, 2012Applicant: GENZYME CORPORATIONInventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
-
Patent number: 6953783Abstract: The invention relates to the modulation of gene expression. In particular, the invention relates to compositions comprising antisense oligonucleotides which inhibit expression of a gene in operable association with protein effectors of a product of that gene, and methods of using the same. In addition, the invention relates to the modulation of mammalian gene expression regulated by methylation.Type: GrantFiled: October 19, 1999Date of Patent: October 11, 2005Assignee: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Robert A. Macleod, William M. Siders, Zuomei Li
-
Publication number: 20030096777Abstract: The invention relates to the modulation of gene expression. In particular, the invention relates to compositions comprising antisense oligonucleotides which inhibit expression of a gene in operable association with protein effectors of a product of that gene, and methods of using the same.Type: ApplicationFiled: May 14, 2002Publication date: May 22, 2003Inventors: Jeffrey M. Besterman, Robert A. MacLeod, William M. Siders, Zuomei Li